Metabolic syndrome - Myths, mechanisms, management;Das metabolische syndrom - Mythen, mechanismen, management

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 20, 2006, Pages 1167-1172

  Bluher M ^a   Stumvoll, M ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Cardiovascular risk factors; Diabetes mellitus; Hyperlipidaemia; Hypertension; Metabolic syndrome; Obesity; Syndrome X

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METFORMIN; RIMONABANT;

CARDIOVASCULAR RISK; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; PATHOPHYSIOLOGY;

HUMANS; METABOLIC SYNDROME X; PREVALENCE; RISK FACTORS;

EID: 33745982910     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-941745     Document Type: Review

References (57)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553
2. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-315
3. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-443
4. Blüher M, Paschke R. Visceral adipose tissue and metabolic syndrome. Dtsch Med Wochenschr 2003; 128: 2319-2323
5. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077
6. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494
7. Colwell JA. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs 2004; 4: 87-106
8. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194
9. Despres JP, Golay A, Sjostrom L Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134
10. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schemthaner G, Schmitz O, Skrha J, Smith U, Taton J PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289
11. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428
12. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-252
13. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 92: 1440-1446
14. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357
15. Festa A, Jr. D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47
16. Gale EAM. The myth of the metabolic syndrome. Diabetologia 2005; 48: 1679-1683
17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Jr. Smith SC, Spertus JA, Costa F American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart. Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752
18. Hanefeld M, Leonhardt W. Das metabolische Syndrom. Dt Gesundheitswesen 1981; 36: 545-551
19. Hanefeld M, Scriba P. Metabolic syndrome. Internist 1996; 37: 679-680
20. Hanefeld M. Postprandial hyperglycaemia: noxious effects on the vessel wall. Int J Clin Pract 2002; 129: 45-50
21. Hauner H. Insulin resistance and the metabolic syndrome - a challenge of the new millennium. Eur J Clin Nutr 2002; 56: S25-29
22. Ibrahim HA, Vora JP. Hypertension in diabetes: a good opportunity to practise evidence-based medicine? A commentary on the UKPDS. United Kingdom Prospective Diabetes Study. J Hum Hypertens 1999; 13: 221-223
23. International Diabetes Federation. Worldwide definition of the metabolic syndrome, (www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf), 2005
24. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689
25. Kahn R, Buse J, Ferrannini E, Stern M American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304
26. King H, Aubert RE, Hermann WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431
27. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350: 2549-2557
28. Kylien E. Studien Hypertonie - Hyperglykämie - Hyperurikä miesyndrome. Zentralblatt für Innere Medizin 1923; 44: 22-29
29. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716
30. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation 2005; 112: 505-512
31. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250
32. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139: 802-809
33. Meigs JB, Sr. D'Agostino RB, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997; 46: 1594-1600
34. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheeny PM, Lipinska I, D'Agostino RB, Wilson PW. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-228
35. Meigs JB. Metabolic syndrome and risk for type 2 diabetes. Exp Rev Endocrinol Metab 2006; 1: 57-66
36. Orchard TJ, Temprosa M, Coldberg R, Haffner S, Ratner R, Marcovino S, Fowler S Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611-619
37. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Okkene IS, Sacco RL, Jr Sallis JF, Jr. Smith SC, Stone NJ, Taubert KA. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-391
38. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737
39. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-620
40. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
41. Reaven GM. Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab 2005; 1: 9-14
42. Rubins HB. Triglycerides and coronary heart disease: implications of recent clinical trials. J Cardiovasc Risk 2000; 7: 339-345
43. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30: 487-496
44. Shen BJ, Todaro JF, Niaura R, McCaffery JM, Zhang J, 3rd Spiro A, Ward KD. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 2003; 157: 701-711
45. Smyth S, Heron A. Diabetes and obesity. The twin epidemics: Market Analysis. Nat Med 2006; 12: 75-80
46. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228
47. Staiger H, Häring HU. Adipocytokines: fat-derived humoral mediators of metabolic homeostasis. Exp Clin Endocrinol Diabetes 2005; 113: 67-79
48. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-3517
49. Thamer C, Machann J, Haap M, Stefan N, Heller E, Schnodt B, Stumvoll M, Claussen C, Fritsche A, Schick F, Haring H. Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects. Diabetes Care 2004; 27: 2726-2729
50. The HOPE study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259
51. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161
52. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanmemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
53. Vague J. The degree of masculine differentiation of obesities, a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr 1956; 4: 20-34
54. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397
55. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a metaanalysis of clinical studies. Diabetes Care 2005; 28: 942-949
56. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Reviews 2000; 21: 697-738
57. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072